Written questions by Evans.

For how long he expects NHS England to continue central funding for the EMIS Web dispensing module

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

What consultation did his Department undertake before NHS England's decision to cease central funding for the EMIS Web dispensing module from 1 April 2026

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

How much central funding does NHS England currently provide to fund the EMIS Web dispensing module

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

Whether he has held recent discussions with NHS England on the future of their centralised funding for the EMIS Web dispensing module

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

What recent discussions he has had with (a) the Dispensing Doctors Association (b) the British Medical Association, and (c) NHS England on NHS England ceasing to centrally fund the EMIS Web dispensing module from 1 April 2026.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

Whether he plans to publish a response to Community Pharmacy England’s recently commissioned survey on abuse in pharmacies.

The Department and NHS England condemn any form of abuse directed at healthcare workers. Pharmacy teams should be able to go to work without fear and have a fundamental right to be safe at work.NHS England has met with Community Pharmacy England to discuss the findings of the survey and how we can further support community pharmacies and their staff.

Pursuant to the answer of 30 March 2026 to WPQ 122758, whether his Department will stipulate who should be triaging in the Elective Single Point of Access Model.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

Pursuant to the answer of 30 March 2026 to WPQ 122758, what professionals will be allowed to triage in the Elective Single Point of Access Model.

NHS England has published technical guidance to secondary care providers and integrated care boards (ICBs) regarding the Elective Single Point of Access Model (SPoA). This sets out governance, quality assurance, and clinical oversight requirements for SPoA. Existing local processes and structures for quality assurance, performance management, and clinical governance remain in place, for instance through National Health Service trusts and ICBs, including specialty-level clinical leadership and senior oversight to ensure this change is implemented safely and appropriately, and that patients who require specialist assessment are referred without delay.Specialist clinical assessment is undertaken within robust clinical governance arrangements, with senior clinical oversight at specialty level to ensure that referrals are managed safely and appropriately, and that patients who require a hospital appointment are referred without delay.

If he has made an assessment of the impact on his Department’s policies of Community Pharmacy England’s recently commissioned survey on abuse in pharmacies.

The Department and NHS England condemn any form of abuse directed at healthcare workers. Pharmacy teams should be able to go to work without fear and have a fundamental right to be safe at work.NHS England has met with Community Pharmacy England to discuss the findings of the survey and how we can further support community pharmacies and their staff.

Pursuant to the answer of 30 March 2026 to WPQ 122758, if his Department will publish a list of all the (a) professional and (b) clinical criteria which staff will need to meet in order to triage in the Elective Single Point of Access Model.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

Pursuant to the answer of 30 March 2026 to WPQ 122758, whether there will be any limitations on what qualifications staff will be required to have in order to triage in the Elective Single Point of Access Model.

NHS England has published technical guidance to secondary care providers and integrated care boards (ICBs) regarding the Elective Single Point of Access Model (SPoA). This sets out governance, quality assurance, and clinical oversight requirements for SPoA. Existing local processes and structures for quality assurance, performance management, and clinical governance remain in place, for instance through National Health Service trusts and ICBs, including specialty-level clinical leadership and senior oversight to ensure this change is implemented safely and appropriately, and that patients who require specialist assessment are referred without delay.Specialist clinical assessment is undertaken within robust clinical governance arrangements, with senior clinical oversight at specialty level to ensure that referrals are managed safely and appropriately, and that patients who require a hospital appointment are referred without delay.

Pursuant to the Answer of 23 March 2026 to Question 120986 on General Practitioners: Contracts, what evidence his Department holds which shows that patients had improved care as a result of changes to Advice and Guidance.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

Pursuant to the Answer of 18 March 2026 to Question 119478 on General Practitioners: Contracts, how he defines ‘avoiding’ in the context of avoiding 1.3 million patients being added to a waiting list.

Advice and Guidance (A&G) is a pre‑referral service used to enable general practitioners (GPs) and hospital specialists, including consultants, to work together to make the best care plans for patients, ensuring patients receive care in the most appropriate setting. A&G requests are distinct from hospital referrals, whereby a patient is added onto a waiting list. A&G does not take away a GP’s right to refer, which remains a matter of clinical judgement.“Avoiding” being added to a waiting list reflects when, following an A&G request, a patient is deemed not to require a secondary care referral at that time. Without A&G, these patients might otherwise have had to wait for an unnecessary appointment and instead are expected to receive more timely care with earlier specialist input. In these cases, the GP may still subsequently refer their patient at any point if they have concerns.Between April 2025 and December 2025, there were nearly 16 million referrals for Referral to Treatment services. For the same period there were over 1.2 million pre-referral A&G requests directed to treatment that is not a secondary care referral at that time, or 45.9% of total A&G requests, and this figure has been updated to reflect the latest data.Additionally, the National Director for Primary Care and Community Services set out further information here: https://www.england.nhs.uk/long-read/letter-specialist-advice-elective-single-point-of-access/

Pursuant to the Answer of 23 March 2026 to Question 120986 on General Practitioners: Contracts, if he will publish the evidence that shows that patients had improved care as a result of changes to Advice and Guidance.

It has not proved possible to respond to the hon. Member in the time available before Prorogation.

What steps will be taken to consider rural GP practices in the review of the Carr-Hill formula.

Phase one of the Carr-Hill review concluded on 31 March, with work currently under way to review options presented by the review team for reforming the formula. Given the complexity of the currently funding model, any changes to the formula will be given careful consideration. Subject to ministerial agreement to the recommendations of the review, the technical development of the new formula will begin. There is currently no confirmed timetable for the conclusion of the next stage of the review.Findings from the review will be published in due course by the National Institute for Health and Care Research and Members of Parliament will be updated once the review findings are available.The purpose of the review is to ensure that funding for general practice is distributed equitably and is targeted towards areas that need it most. As part of this, the review has given consideration to the unavoidable costs based on geographical areas, including delivering services in rural areas.

Pursuant to the Answer of 23 March 2026 to Question 121056 on General Practitioners: Contracts, when the review of the Carr-Hill formula will conclude; and when he plans to publish its findings.

Phase one of the Carr-Hill review concluded on 31 March, with work currently under way to review options presented by the review team for reforming the formula. Given the complexity of the currently funding model, any changes to the formula will be given careful consideration. Subject to ministerial agreement to the recommendations of the review, the technical development of the new formula will begin. There is currently no confirmed timetable for the conclusion of the next stage of the review.Findings from the review will be published in due course by the National Institute for Health and Care Research and Members of Parliament will be updated once the review findings are available.The purpose of the review is to ensure that funding for general practice is distributed equitably and is targeted towards areas that need it most. As part of this, the review has given consideration to the unavoidable costs based on geographical areas, including delivering services in rural areas.

What discussions he has had with the National Institute for Health and Care Research on the development of UK based research about (a) emerging drugs and (b) treatment options for patients with MND.

Government responsibility for delivering motor neurone disease (MND) research is shared between the Department of Health and Social Care, with research delivered by the National Institute for Health and Care Research (NIHR), and the Department for Science, Innovation and Technology, with research delivered via UK Research and Innovation, primarily by the Medical Research Council.The Government is investing in MND research across a range of areas, including possible treatments. For example, the MND Translational Accelerator, supported by £6 million of Government funding, has twelve projects all aimed at speeding up the development of treatments for MND.The NIHR has also invested £8 million into EXPERTS-ALS, a pre-clinical study which is designed to accelerate the identification and testing of the most promising treatment candidates for treating amyotrophic lateral sclerosis (ALS), the most common form of MND. This will connect to the later phase platform trial, MND SMART.In August 2025, the Medicines and Healthcare Products Regulatory Agency approved Tofersen to treat SOD1-ALS, a rare form of MND. Research into Tofersen was supported by NIHR’s Sheffield Biomedical Research Centre, and all three trial phases were delivered by the NIHR’s Research Delivery Network, demonstrating tangible impact of NIHR funded research into MND.The NIHR continues to welcome high quality applications for research into MND. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to the public and health and care services, value for money, and scientific quality.Welcoming applications on MND to all NIHR programmes enables maximum flexibility both in terms of the amount of research funding a particular area can be awarded, and the type of research which can be funded.

Whether he has had recent discussions with (a) NHS England and (b) integrated care boards on the potential impact of the adequacy of physical therapy services on patients' cognitive ability.

Department officials hold regular discussions with NHS England on how integrated care boards are commissioning and delivering community health services, which includes physical therapy.Access to sufficient, high-quality physical therapy is important in supporting patients’ physical function and overall wellbeing. Appropriate, individualised therapy can help to improve mobility, manage pain, and support participation in day-to-day activities. These outcomes may also contribute to maintaining independence and promoting engagement in activity, which can be beneficial for cognitive health and wider quality of life.The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it. The plan will articulate the changes for different professional groups.

In relation to the Medium Term Planning Framework published by NHS England in October 2025, which 10 specialities each ICB has identified as the most effective for the use of Advice and Guidance.

As set out in the Medium-Term Planning Framework, National Health Service providers of Referral to Treatment consultant-led care are expected to prioritise Advice and Guidance (A&G) across at least ten specialties where it will have the greatest overall benefit. The ten specialties are selected locally at provider-level. General practice should be involved in discussions to decide on which are the most appropriate and we expect integrated care boards (ICBs) to support the use of A&G through their strategic commissioning for 2026/27. We do not centrally hold information regarding which specialties providers have selected. Regarding the 25% aim, the National Director for Primary Care and Community Services made clear there is no national target. Further information is available at the following link: https://www.england.nhs.uk/long-read/letter-specialist-advice-elective-single-point-of-access/ The 2026/27 GP Contract embeds the £82 million of funding from the previous A&G enhanced service, into core practice funding. Embedding A&G in the core contract recognises it as routine clinical practice, removes annual signups, and provides more predictable funding while supporting consistent patient pathways. A general practitioner’s (GP’s) clinical decision to refer remains unchanged and GPs should continue to make a clinical decision to refer for specialist care where that is in the patient’s best interest.

What recent discussions the UK Neuro Forum has had on (a) care pathways, (b) treatment options and (c) access to drugs for patients with motor neurone disease.

The UK Neuro Forum brings key stakeholders together to share learnings across the system and to discuss challenges, best practice examples, and potential solutions for improving the care of people with neurological conditions, including motor neurone disease (MND).At the second meeting of the UK Neuro Forum on 10 September 2025, one of the key areas of discussion was cross-border care. The forum met again most recently on 18 March and discussed workforce challenges.